Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration (the "FDA") for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. The Company is scheduled to present at 2:30pm Eastern Time the same day via webcast.
马尔文，宾夕法尼亚州，2024年11月20日（全球新闻通讯）-- neuronetics公司（纳斯达克：STIM）是一家专注于设计、开发和销售改善神经健康障碍患者生活质量的医疗科技公司，今天宣布管理团队将在2024年12月4日（星期三）派杰投资第36届年度医疗会议上进行演讲。公司定于同一天东部时间下午2:30通过网络直播进行演讲。
A live audio webcast of the presentation will be available online at the investor relations page of the Company's website at ir.neuronetics.com.
该演示的音频直播将在公司网站的投资者关系页面 ir.neuronetics.com 上提供。
About Neuronetics
Neuronetics，Inc.相信心理健康和身体健康一样重要。作为神经科学的全球领导者，神经优美正在通过其对心理健康的NeuroStar高级疗法重新定义患者和医生的预期。NeuroStar是一种非药物、非侵入性的治疗方法，可以改善神经健康状况下的生活质量，当传统药物无效时。 NeuroStar适用于治疗抑郁发作，在当前情况下，降低那些可能同时表现出共病性焦虑症状成年患者的焦虑症状。它也获得FDA批准作为辅助治疗青少年MDD的患者。NeuroStar Advanced Therapy是治疗成人MDD的领先TMS治疗，已提供超过640万次治疗。神经优美致力于通过提供卓越的治疗，为患者带来非凡的疗效，以改变生命。有关安全和处方信息，请访问 。
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration (the "FDA") for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.
neuronetics公司相信心理健康与身体健康同样重要。作为神经科学的全球领导者，neuronetics正在重新定义患者和医生的期望，通过其NeuroStar爱文思控股治疗心理健康。NeuroStar是一种非药物、非侵入性的治疗，在传统药物未能帮助的情况下，可以改善患有神经健康状况的人的生活质量。NeuroStar爱文思控股治疗系统已获得美国食品和药物管理局（“FDA”）的批准，适用于成年抑郁障碍患者，作为强迫症成年患者的辅助治疗，并减少可能出现共病焦虑症状（焦虑型抑郁症）的成年抑郁症患者的焦虑症状，以及作为针对15-21岁青少年抑郁症患者MDD治疗的首要辅助措施。NeuroStar爱文思控股治疗是针对成年抑郁症的领先TMS治疗，已提供超过690万次治疗。NeuroStar拥有世界上最大的抑郁症结果注册库，是任何TMS治疗系统中最大的临床数据集。neuronetics致力于通过提供卓越的治疗来改变生活，这种治疗产生了非凡的效果。有关安全性和处方信息，请访问 NeuroStar.com。
Investor Contact:
投资者联系人：
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Mike Vallie或者Mark Klausner
ICR 医疗保健
443-213-0499
ir@neuronetics.com
Media Contact:
媒体联系：
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
